







Outline

Why

- Need for more efficient tools for chemcial risk assessment
- Need to better use our existing and future data and knowledge

What

- The Adverse Outcome Pathway framework
- o Purpose, definition


How

- o Relational "knowledgebase"
- o Guidance
- Evaluation
- Training and free course

Issue #1: too many chemicals, current system inadequate

- e.g. tens of thousands of chemicals await assessment
- e.g. 95% clinical failure rate for new drugs in spite of increased spending
- Faster, more relevant approaches
 needed across sectors





Issue #2: The need to better leverage our existing knowledge

Too much data!

- Decades of research and testing data
- o Global scientific output doubles every 9 years

Where is the data?!

- o Journal articles, reports, laboratory notebooks, agency archives,
- Institutional and government databases







Better access, better organization leads to better understanding








- o PDFs
- o Fragmented
- o Siloed
- Proprietary

- o Searchable
- o Machine-readable
- o Linked
- Facilitating collaboration
- Avoiding duplication


(adapted from D. Villeneuve)

Adverse Outcome Pathway framework: linking molecular initiation to adverse outcomes



- How to use molecular understanding to make better decisions about chemical safety
- Provides a framework for collecting, organizing and evaluating biological information

AOPs: Linking molecular information to adverse outcomes




A sequence of events


- o beginning with initial interactions of a stressor with a biomolecule in a target cell or tissue (the molecular initiating event),
- progressing through a dependent series of intermediate events (key events)
- o culminating with an adverse outcome*

*if compensatory mechanisms are overwhelmed

AOPs: Provides scaffold for organizing, evaluating and understanding data




Essential elements of an AOP



- Key Events (KEs) nodes
 - Change in biological or physiological state
 - Measurable and essential for progression
- Molecular Initiating Event (MIE): specialized KE that represents the initial point of stressor interaction with the organism
- Adverse Outcome (AO): specialized KE of regulatory significance
- Key Event Relationships (KERs)
 - Connection between two key events
 - o Critical for assembling evidence in support of the AO
 - o Facilitates inference or extrapolation


Building an AOP



- o Start anywhere
 - but one AOP = one MIE leading to one AO as a pragmatic unit
- Gather all existing knowledge
 - Not every detail, but critical steps or check-points
 - Collaboration is encouraged
- Evaluate and document the information
 - Refer to extensive OECD guidance
- o Translate and capture information as a pathway in the AOP Wiki

Fundamental principles of AOP development





AOPs are modular

Key events and relationships can be shared by multiple AOPs


AOPs are living documents

- AOP descriptions can be expected to evolve over time
- As descriptions are updated and expanded all AOP descriptions they link to update automatically

AOP networks will emerge and are the basis for prediction

AOP Knowledgebase: an international partnership





AOP Wiki: information storage, linkage and evaluation

- Captures and organizes all information and supporting documentation for AOP elements
- Supported by extensive guidance, tutorials and an online course
- Is designed to enable rigorous evaluation and scientific review



Publically accessible since 2014 www.aopwiki.org

AOP WIKI: Home page

AOPWiki AOPs Key Events KE Relationships Stressors sign in sign up

AOP Welcome

Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)













This wiki represents a joint effort between the European Commision - DG Joint Research Centre (JRC) and U.S Environmental Protection Agency (EPA). This serves as one component of a larger OECD-sponsored AOP Knowledgebase (AOP-KB) effort and represents the central repository for all AOPs developed as part of the OECD AOP Development Effort by the Extended Advisory Group on Molecular Screening and Toxicogenomics. The other major components of this knowledgebase are Effectopedia, produced by the Organisation for Economic Co-operation and Development (OECD), the AOP Xplorer, produced by the US Army Corps of Engineers - Engineering Research and Development Center, and the Intermediate Effects DB produced by the JRC. All AOPs from the AOP Knowledgebase are available via the e.AOP.Portal, which is the primary entry point for the AOP-KB.

This wiki is based upon the Chemical Mode of Action wiki developed by the EPA under the auspices of the WHO International Programme on Chemical Safety (IPCS) Mode of Action Steering Group.

Disclaimer


The content of this wiki is the sole responsibility of the individual contributors and does not necessarily represent the views of the authors' organizations nor the organizations responsible for development of the AOP-Wiki or the AOP-KB. Mention of trade names or commercial products does not constitute endorsement by any of these organizations.

Contents

- 1. Announcements
- Event Components
 Coming Soon
- 2. AOP Welcome
 - Welcome to the
 Collaborative Adverse
 Outcome Pathway Wiki
 (AOP-Wiki)
 - 2. Disclaimer
- 3. Help
 - 1. Before you start
- New Training Course
 Available
- Requesting Access to Create and Edit AOPs
- Frequently Asked
 Questions
- 4. Wiki 2.0 Upgrade
 - 1. User Account Migration
- Confirm AOP Information
 Following Migration
- Notable Changes for Authors
- 4. Wiki 2.1 Release
- Firefox Users Redirecting to Old Wiki

Help About FAQ Metrics

AOP WIKI: search "liver fibrosis"



Help


AOP 38 Summary

AOPWiki AOPs Key Events KE Relationships Stressors Kate ▼

Summary of the AOP 0

Events: Molecular Initiating Events (MIE) 📀 Key Events (KE) 💿 Adverse Outcomes (AO) 📀

| Sequence | Туре | Event ID | Title | Short name |
|----------|------|----------|--|--|
| 1 | MIE | 244 | Alkylation, Protein | Alkylation, Protein |
| 2 | KE | 55 | N/A, Cell injury/death | N/A, Cell injury/death |
| 3 | KE | 134 | Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) | Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
| 4 | KE | 276 | Up Regulation, TGFbeta1 expression | Up Regulation, TGFbeta1 expression |
| 5 | KE | 265 | Activation, Stellate cells | Activation, Stellate cells |
| 6 | KE | 68 | Accumulation, Collagen | Accumulation, Collagen |
| 7 | AO | 344 | N/A. Liver fibrosis | N/A, Liver fibrosis |



AOP WIKI: KER and AOP confidence evaluation

| Biological Plausibility: between KE upstream and KE downstream? | | | | | | |
|--|--|--|--|--|--|--|
| High (strong): Extensive understanding of KER | Moderate: KER is plausible | Low (weak): some empirical support | | | | |
| Essentiality: are downstream KEs prevented if upstream KE's blocked? | | | | | | |
| High (strong): direct evidence from experimental studies | Moderate: indirect evidence | Low (weak) No or contradictory evidence | | | | |
| Empirical Evidence: amount, quality, consistent, inconsistent? | | | | | | |
| High (strong): extensive evidence for temporal, dose-response | Moderate: multiple reports of consistent evidence, some inconsistent | Low (weak): limited or no studies and/or significant inconsistencies | | | | |

List of AOPs

AOPWIKI AOPS Key Events KE Relationships Stressors Kate ▼

API

API


With OECD status With SAAOP status

Recent AOPS

Find by ID

Find by ID

AOPs



Help About FAQ Downloads Metrics

OECD AOP Development Programme

Extended Advisory Group for Molecular Screening & Toxicogenomics (EAGMST)

- O Guidance, users Handbook
- o Review
- Training

Task force on Hazard Assessment (TFHA)

- Guidance for use of AOPs in regulatory decision making
- Integrated Approaches to Testing and Assessment (IATA)



Society for the Advancement of AOPS


- Not officially part of the OECD programme
- Any person active in developing an AOP in the wiki can join
- Is another way to enter the AOP wiki
- o Provides "gardening" and other support functions
- www.saaop.org

OECD AOP Development Programme

AOP Wiki Access: three levels

- 1. Read access: anyone can access the wiki, search and read entries
- 2. Commenter access: a self-created account is needed to leave comments
 - Create an account on the wiki
- 3. Author access: to write and edit AOPs
 - must be requested through the wiki
 - You should have a familiarity with the wiki and desire to build an AOP

Work Process for Development and Review of AOPs through OECD



OECD Guidance for developing AOPs


Guidance Document for Developing and Assessing AOPs (2017) Series on Testing & Assessment No. 233

OECD User's Handbook Supplement to the Guidance Document for Developing and Assessing AOPs (2017)

Series on Testing & Assessment No. 233 Series on Adverse Outcome Pathways No. 1

| Section of AOP Wiki | Section of Handbook |
|--|---------------------|
| AOP Description | Section 1 |
| KE descriptions (unique pages) | Section 2 |
| KER descriptions (unique pages) KER evaluation | Section 3 |
| Overall AOP assessment | Section 4 |

AOP Online Training Course




https://humantoxicologyproject.org/about-pathways-2/aop-online-course/

Run:

https://aopwiki.org/

Current state of the AOP Wiki



23 June 2017 D. Villeneuve

The more participation, the better it will be!